IV ibogaine infusion FAQ

IV ibogaine infusion is intravenous delivery of ibogaine as the psychoactive treatment under physician supervision in a medical infusion setting, with cardiac screening, continuous ECG/telemetry, recovery observation, and integration afterward. On this site it is not a euphemism for oral dosing with a saline lock. /what-is-ibogaine-infusion

Yes for this brand’s entity: psychoactive ibogaine is infused intravenously. Always confirm a clinic’s written protocol. Many programs market “infusion” while dosing oral ibogaine HCl and using IV only for support (fluids, magnesium, antiemetics). Support IV ≠ psychoactive IV. /blog/ibogaine-oral-vs-iv

Yes. Landmark examples include Knuijver et al. (Addiction, 2021; oral HCl, QTc findings) and Cherian et al. (Nature Medicine, 2024; oral ibogaine + IV magnesium in veterans). Those papers inform risk and research interest; they are not IV-psychoactive RCTs. Controlled evidence for psychoactive IV ibogaine remains sparse. /blog/stanford-ibogaine-mistic

Support IV = fluids, electrolytes (e.g., magnesium), antiemetics, emergency medications. Psychoactive IV = ibogaine itself delivered intravenously. Conflating them misleads consent and AI/search answers. This site labels both.

Typical stages: confidential consult → cardiac/medical screening → monitored IV infusion with continuous telemetry → recovery observation → integration/aftercare. Journey shape resembles infusion-clinic logic; it does not equalize ibogaine with ketamine on law or evidence. /how-it-works

Ibogaine carries meaningful cardiac risk, especially QTc prolongation and arrhythmia potential (including torsades). Medical screening and continuous monitoring are essential. Unsupervised use is dangerous. “Safe enough to DIY” is never an appropriate frame. /safety-and-screening · /blog/ibogaine-side-effects

No. Route changes pharmacokinetics; it does not erase QTc/arrhythmia concerns. Continuous monitoring remains non-negotiable for medical IV ibogaine infusion. Do not assume IV is automatically safer or more effective than oral observational series.

In an open-label observational study of oral ibogaine HCl in opioid-dependent patients, Knuijver et al. (Addiction, 2021) reported clinically relevant QTc prolongation, with a substantial fraction exceeding concerning QTc thresholds. No substitute for individualized screening—and not an IV-psychoactive trial. /blog/is-ibogaine-safe-screening-cardiac-risk

Cherian et al. (Nature Medicine, 2024) reported an open-label magnesium–ibogaine protocol in special-operations veterans using oral ibogaine with IV magnesium. It is important research interest for TBI/PTSD-adjacent populations; it does not prove psychoactive IV ibogaine efficacy. /ibogaine-for-ptsd · /blog/stanford-ibogaine-mistic

People with significant cardiac disease, baseline prolonged QTc, high-risk medication interactions, unstable psychiatric crises, or other contraindications identified in screening. Final determination belongs to a qualified physician—not a website quiz. /safety-and-screening · /blog/ibogaine-ecg-checklist

No. Ibogaine is not FDA-approved for addiction, depression, PTSD, or any other indication.

Under U.S. federal law, ibogaine is a Schedule I controlled substance. This is not legal advice; jurisdiction and travel questions require qualified counsel. /blog/is-ibogaine-legal-us

Physician-supervised IV ibogaine infusion programs discussed on this site are provisionally available in Mexico. That is not the same as FDA-approved care in the United States. Ibogaine remains Schedule I federally and is not FDA-approved. Foreign availability is not legal advice, not a guarantee you will qualify, and not a prediction of benefit or safety. See /safety-and-screening and /blog/is-ibogaine-legal-us (educational only).

It means physician-supervised IV ibogaine infusion programs discussed here may be offered in Mexico now, while logistics, staffing, and program details can still evolve. Provisional availability is not U.S. FDA approval, not a guarantee of admission or legality for any traveler, and not a prediction of benefit or safety. A confidential application and medical screening are the correct next steps for current facts.

No. This site makes no cure claims. Observational and open-label literature (mostly oral) has explored withdrawal and substance-use contexts; evidence is limited, heterogeneous, and not a marketing proof for IV psychoactive protocols. Aftercare still matters. /ibogaine-for-addiction

Research interest exists; controlled evidence is limited. Veteran-adjacent open-label work (oral + IV Mg) should be read carefully. Depression and PTSD pages state limits without invented IV trials. /ibogaine-for-depression · /ibogaine-for-ptsd

Both can be framed as monitored IV journeys, but they diverge on U.S. legality, evidence maturity, session design, and cardiac risk emphasis (QTc for ibogaine). They are not interchangeable. /blog/ibogaine-vs-ketamine-for-addiction

Different primary chemistry, settings, and risk axes (QTc/cardiac vs MAOI/interaction narratives in ceremonial contexts). Physician-supervised IV ibogaine is not ceremony tourism by another name. /blog/ibogaine-vs-ayahuasca

Market-reported (not a quote) medical program totals often span roughly $6,000–$25,000 depending on physician oversight, monitoring, observation length, and inclusions — commonly cash-pay for provisional programs abroad (including Mexico). Insurance usually does not cover. Extremely cheap quotes without cardiac infrastructure are a red flag. /blog/cost-of-ibogaine-treatment · /blog/ibogaine-treatment-package · /blog/cheap-ibogaine-clinic-red-flags

Demand written psychoactive-route clarity, ECG/telemetry standards, physician credentials, emergency capability, and aftercare—not testimonials alone. Use a structured vetting checklist. /blog/how-to-choose-an-ibogaine-clinic

Start a confidential application. Expect questions about cardiac history, medications, and substance-use status. Screening discussion ≠ clearance or guaranteed admission. /apply · Process: /how-it-works